Navigating Your Path to Wellness: What is the Average Semaglutide Dose for Effective Weight Loss?

Last reviewed: June 15, 2026

Last updated: June 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no meaningful "average" semaglutide dose for weight loss, because the labeled schedule is not an average — it is a defined escalation with defined maintenance options, and which one a person ends on is a prescriber decision. The Wegovy prescribing information sets a usual recommended maintenance dosage of 2.4 mg once weekly for weight reduction in adults, with 1.7 mg as an alternative and, following a March 2026 revision, a maximum of 7.2 mg once weekly for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. Reporting what the label says is useful; treating it as a target to aim for is not.

The Labeled Schedule, As Written

The label sets a starting dosage of 0.25 mg once weekly and a published escalation table: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and maintenance from week 17 onward. The stated purpose of staging it is to reduce the risk of gastrointestinal adverse reactions.

The label also instructs that if a patient does not tolerate a dose during escalation, the prescriber may consider delaying escalation for four weeks. That single sentence is why an average is the wrong statistic: the schedule is explicitly permitted to vary by person.

Maintenance Depends on the Indication

This is the part most summaries omit. For weight reduction in adults, the maintenance dosage is either 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended, and the label directs prescribers to consider treatment response and tolerability when selecting between them.

For cardiovascular risk reduction in adults, maintenance is either 2.4 mg (recommended) or 1.7 mg. For weight reduction in pediatric patients aged 12 and older, it is 2.4 mg (recommended) or 1.7 mg. For noncirrhotic MASH with moderate to advanced fibrosis, it is 2.4 mg, reducible to 1.7 mg if not tolerated, with reescalation considered. Same drug, four different maintenance frameworks.

The 7.2 mg Addition and What Supported It

The higher maintenance option came from a 72-week trial reported in the label that enrolled 1,407 patients with obesity, excluding type 2 diabetes, randomized 5:1:1 to 7.2 mg, 2.4 mg or placebo, with escalation over 20 weeks followed by 52 weeks on maintenance. Mean baseline body weight was 113 kg and mean BMI 39.9 kg/m².

In that trial, 5.4% of patients on 7.2 mg and 1% on placebo permanently discontinued treatment because of adverse reactions. A higher dosage is not simply a bigger version of the same experience, and the label frames access to it as conditional on having tolerated 2.4 mg for at least four weeks.

Ozempic Uses a Different Ladder Entirely

Because people frequently conflate the two, it is worth stating: the Ozempic label starts at 0.25 mg once weekly for four weeks, increases to 0.5 mg, and permits 1 mg and then 2 mg at four-week intervals if additional glycemic control is needed. The maximum recommended dosage is 2 mg once weekly.

Ozempic has no weight-management indication — its three indications are all in adults with type 2 diabetes — so its dosing ladder was built around glycemic and cardiorenal endpoints. Applying a Wegovy maintenance number to an Ozempic prescription, or vice versa, is a category error.

Why "Average" Misleads in Practice

Averages describe populations. A person on 1.7 mg because 2.4 mg was not tolerated is not underdosed; the label names 1.7 mg as a maintenance option and directs prescribers to weigh response and tolerability. A person still at 1 mg in month four may be following a deliberately delayed escalation.

The trials themselves reflect this. In the pooled weight-reduction studies, 6.8% of treated patients discontinued because of adverse reactions versus 3.2% on placebo, most commonly for nausea, vomiting and diarrhea. Tolerability is a real constraint, not a failure of resolve.

What Determines Your Schedule

Your prescriber, working from your medical history, your other medications, the labeled contraindications, and how you are actually responding over time. Nothing in the labeling assigns that decision to the patient, and nothing in it supports selecting a dosage by reference to what other people are taking.

PlexusDx protocols run through a clinical intake and a prescriber, dispensed from licensed 503A compounding pharmacies. Compounded semaglutide is not an FDA-approved finished product and is not reviewed by the FDA for safety, effectiveness or quality before marketing. The FDA has reported adverse events that may relate to compounded products used at doses beyond approved labeling, which is one more reason dosage is not a consumer decision.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What is the maintenance dosage of Wegovy for weight reduction in adults?

The Wegovy prescribing information names either 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended, and directs prescribers to consider treatment response and tolerability when selecting between them. Following a March 2026 revision, the dosage may be increased to a maximum of 7.2 mg once weekly for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated.

How long is the labeled escalation schedule?

The published table runs 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and maintenance from week 17 onward. The label states the staging exists to reduce the risk of gastrointestinal adverse reactions and instructs prescribers to consider delaying escalation for four weeks if a dose is not tolerated.

Is 1.7 mg an inadequate dose?

No. The Wegovy label names 1.7 mg as a maintenance option for weight reduction in adults, for cardiovascular risk reduction, for pediatric patients aged 12 and older, and as a reduced maintenance dosage for noncirrhotic MASH if 2.4 mg is not tolerated. The label directs prescribers to weigh treatment response and tolerability rather than defaulting to the highest available dosage.

Does Ozempic use the same dosing as Wegovy?

No. The Ozempic label starts at 0.25 mg once weekly for four weeks, increases to 0.5 mg, and permits 1 mg and then 2 mg at four-week intervals if additional glycemic control is needed, with a maximum recommended dosage of 2 mg once weekly. Ozempic has no weight-management indication; its three indications are all in adults with type 2 diabetes.

Why should I not aim for a specific dose?

Because the label assigns the decision to a prescriber and conditions it on tolerability and response. The FDA has separately reported adverse events that may relate to patients prescribed compounded semaglutide or tirzepatide at doses beyond approved labeling, including more product per dose, more frequent dosing, or faster escalation. Dosage is a clinical judgment, not a performance target.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.